• research
• publications

Recent Publications

• Landau H, Pandit-Taskar N, Hassoun H, Cohen A, Lesokhin A, Lendvai N, Drullinsky P, Schulman P, Jhanwar S, Hoover E, Bello C, Riedel E, Nimer S, Comenzo RL. Sequential administration of bortezomib, liposomal doxorubicin and dexamethasone (BDD) followed by thalidomide and dexamethasone (TD) is effective treatment for patients with untreated high-risk or primary resistant multiple myeloma (MM). Submitted for publication.
• Shah, JJ, Cohen AD, Zonder JA, Kaufman JL, Burt SM, Freeman BB, Rush S, Ptaszynski AM, Orlowski RZ, Lonial S. Phase I trial of ARRY-520 in relapsed/refractory multiple myeloma (RR MM). J Clin Oncol. 2010;28:15s. (suppl; abstr 8132).
• Cohen AD*, Schaer DA*, Liu C, Li Y, Hirschhorn-Cymerman D, Kim SC, Diab A, Rizzuto G, Duan F, Perales MA, Merghoub T, Houghton AN, Wolchok JD. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. Plos ONE. 2010;5:e10436.
• Cohen AD, Lu P, Gnjatic S, Hoffman J, Ritter E, Zhou P, Teruya-Feldstein J, Wang L, Jungbluth A, Koehne G, Hassoun H, Jhanwar S, Nimer S, Comenzo RL. Prognostic significance of cancer-testis antigen expression and immunity in newly-diagnosed multiple myeloma. Lymphoma and Myeloma 2009: An International Congress on Hematologic Malignancies, New York, NY. Abstract #O-00003.
• Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA, Jagasia M, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Tricot G, Vose JM, Weber D, Yahalom J, Yunus F. NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. Journal of the National Comprehensive Cancer Network. 2009;7:908-42.
• Hirschhorn-Cymerman D, Rizzuto GA, Merghoub T, Cohen AD, Avogadri F, Lesokhin AM, Weinberg AD, Wolchok JD, Houghton AN. OX40 engagement and chemotherapy combination provides potent anti- tumor immunity with concomitant regulatory T cell apoptosis. Journal of Experimental Medicine. 2009;206:1103-16.
• Duan F, Lin Y, Liu C, Engelhorn ME, Cohen AD, Curran M, Sakaguchi S, Merghoub T, Terzulli S, Houghton AN, Wolchok JD. Immune rejection of mouse tumors expressing mutated self. Cancer Research. 2009;69:3545-53.
• Lebovic D, Hoffman J, Levine BM, Hassoun H, Landau H, Goldsmith Y, Maurer MS, Steingart RM, Cohen AD, Comenzo RL. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. British Journal of Haematology. 2008;143:369-73.
• Hassoun H, Flombaum C, D’Agait VD, Rafferty BT, Cohen A, Klimek VM, Boruchov A, Kewalramani T, Reich L, Nimer SD, Comenzo RL. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplantation. 2008;42:405-12.
• Comenzo RL, Steingart RM, Cohen AD. Comment on “High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.” New England Journal of Medicine. 2008;358:92.
• Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, Levine B, Filippa D, Riedel E, Kewalramani T, Stubblefield M, Fleisher M, Nimer S, Comenzo RL. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain (AL-) amyloidosis: results of a phase II trial. British Journal of Haematology. 2007;139:224-33.
• Perales M-A, Diab A, Cohen AD, Huggins DW, Guevara-Patino JA, Hubbard VM, Engelhorn ME, Kochman AA, Eng JM, Mortazavi F, Alpdogan O, Terwey TH, Heller G, Wolchok JD, Houghton AN, van den Brink MRM. DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hematopoietic stem cell transplantation. Journal of Immunologo. 2006;177:4159-67.
• Cohen AD, Diab A, Perales M-A, Wolchok JD, Rizzuto G, Merghoub T, Huggins D, Liu C, Turk MJ, Restifo NP, Sakaguchi S, Houghton AN. Agonist anti–GITR antibody enhances vaccine-induced CD8+ T-cell responses and tumor immunity. Cancer Research. 2006;66: 4904-12.
• Guevara-Patino JA, Engelhorn ME, Turk MJ, Liu C, Duan F, Rizzuto G, Cohen AD, Merghoub T, Wolchok JD, Houghton AN. Optimization of a self-antigen for presentation of multiple epitopes in cancer immunity. Journal of Clinical Investigation. 2006;116:1382-90.
• Hassoun H, Reich L, Klimek VM, Dhodapkar M, Cohen A, Kewalramani T, Zimman R, Drake L, Riedel ER, Hedvat CV, Teruya-Feldstein J, Filippa DA, Fleisher M, Nimer SD, Comenzo RL. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. British Journal of Haematology. 2006;132:155-61.
• Cohen AD, Zhou P, Xiao Q, Fleisher M, Kalakonda N, Akhurst T, Moscowitz C, Dhodapkar MV, Teruya-Feldstein J, Filippa D, Comenzo RL. Systemic AL amyloidosis due to non-Hodgkin’s lymphoma: an unusual clinicopathologic association. British Journal of Haematology. 2004;124: 309-14.

Book Chapters and Reviews

• Khan S, Cohen AD. Experimental approaches in the treatment of multiple myeloma. Therapeutic Advances in Hematology. 2011 (in press).
Cohen AD, Schaer DA, Wolchok JD. GITR. In: Marshall JL, Weiner L, Gelmann E, Kaufmann H, Wellstein A, eds. Encyclopedia of Cancer Targets. New York, NY: Springer, 2011 (in press).
• Cohen AD and Comenzo RL. Light-chain (AL) amyloidosis: diagnosis, prognosis, and therapy. Hematology (Am Soc Hematol Educ Program) 2010; 287-294, 2010.
• Schaer DA, Cohen AD, Wolchok JD. Anti-GITR antibodies - potential clinical applications for immunotherapy. Curr. Opin. Invest. Drugs 11; 1378-1386, 2010.
• Cohen AD and Comenzo RL. High-dose therapy in AL amyloidosis. In: Gertz M and Rajkumar SV, eds. Diagnosis and Treatment of Amyloidosis. Totowa, NJ: Humana Press, 2010, 165-178.
• Cohen AD, Zhou P, Reich L, Hassoun H, Teruya-Feldstein J, Filippa DA, Clark B, Stubblefield M, Fleisher M, Nimer SD, Comenzo RL. Risk-adapted melphalan with stem cell transplant (SCT) and adjuvant dexamethaxone +/- thalidomide achieves low treatment-related mortality and high hematologic response rates. In: Skinner M, ed. XIth International Symposium on Amyloidosis. Boca Raton, FL: Taylor & Francis Group LLC, 2007.
• Cohen AD and Wolchok JD. DNA vaccines against cancer. In: Kaufman HL and Wolchok JD, eds. General Principles of Tumor Immunotherapy. Springer, 2007.
• Stan R, Wolchok JD, Cohen AD. DNA vaccines against cancer. Hematology/Oncology Clinics of North America. 2006;20:613-36.
• Cohen AD and Wolchok JD. DNA vaccines for melanoma. In: Giaconne G, Schilsky R, and Sondel P, eds. Cancer Chemotherapy and Biological Response Modifiers, Annual 22. Oxford: Elsevier, 2005.
• Diab, A, Cohen AD, Alpogan O, Perales M-A. IL-15: targeting CD8+ T cells for immunotherapy. Cytotherapy. 2005;7:23-35.